Distribution of Plasma One-Carbon Metabolism Factors and Amino Acids Profile in Depression State Treated with Paroxetine: A Model Study

Document Type : Original Article


1 Department of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran

2 Department of Biochemistry and Functional Genomics, University de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada

3 Department of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran


Objective: Stress may have an important role in the origin and progress of depression and can impair metabolic
homeostasis. The one-carbon cycle (1-CC) metabolism and amino acid (AA) profile are some of the consequences
related to stress. In this study, we investigated the Paroxetine treatment effect on the plasma metabolite alterations
induced by forced swim stress-induced depression in mice.
Materials and Methods: In this experimental study that was carried out in 2021, thirty male NMRI mice (6-8 weeks
age, 30 ± 5 g) were divided into five groups: control, sham, paroxetine treatment only (7 mg/kg BW/day), depression
induction, and Paroxetine+depression. Mice were subjected to a forced swim test (FST) to induce depression and then
were treated with Paroxetine, for 35 consecutive days. The swimming and immobility times were recorded during the
interventions. Then, animals were sacrificed, plasma was prepared and the concentration of 1-CC factors and twenty
AAs was measured by spectrophotometry and high-performance liquid chromatography system (HPLC) techniques.
Data were analyzed by SPSS, using One-Way ANOVA and Pearson Correlation, and P<0.05 was considered significant.
Results: Plasma concentrations of phenylalanine, glutamate, aspartate, arginine, ornithine, citrulline, threonine,
histidine, and alanine were significantly reduced in the depression group in comparison with the control group.
The Homocysteine (Hcy) plasma level was increased in the Paroxetine group which can be associated with
hyperhomocysteinemia. Moreover, vitamin B12, phenylalanine, glutamate, ornithine, citrulline, and glycine plasma
levels were significantly reduced in the depression group after Paroxetine treatment.
Conclusion: This study has demonstrated an impairment in the plasma metabolites’ homeostasis in depression and
normal conditions after Paroxetine treatment, although, further studies are required.


Main Subjects

  1. Takagi K, Tanahashi N, Amagasu N, Mizuno K, Kawanokuchi J, Yi G, et al. Effect of manual acupuncture stimulation at “Bai-Hui”(GV 20) or “Yintáng”(Ex-HN3) on depressed rats. J Acupunct Meridian Stud. 2017; 10(1): 26-32.
  2. Polak M, Nowicki GJ, Naylor K, Piekarski R, Ślusarska B. The prevalence of depression symptoms and their socioeconomic and health predictors in a local community with a high deprivation: a cross-sectional studies. Int J Environ Res Public Health. 2022; 19(18): 11797.
  3. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000; 69(2): 228-232.
  4. Lyon P, Strippoli V, Fang B, Cimmino L. B vitamins and one-carbon metabolism: implications in human health and disease. Nutrients. 2020; 12(9): 2867.
  5. Almeida OP, Ford AH, Hirani V, Singh V, vanBockxmeer FM, Mc- Caul K, et al. B vitamins to enhance treatment response to antidepressants in middle-aged and older adults: results from the B-VITAGE randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2014; 205(6): 450-457.
  6. Xu HB, Fang L, Hu ZC, Chen YC, Chen JJ, Li FF, et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. 2012; 200(2-3): 1054- 1057.
  7. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6): 1155-1158.
  8. Islam MR, Ali S, Karmoker JR, Kadir MF, Ahmed MU, Nahar Z, et
  9. Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. BMC Psychiatry. 2020; 20(1): 333.
  10. Ogawa S, Koga N, Hattori K, Matsuo J, Ota M, Hori H, et al. Plasma amino acid profile in major depressive disorder: Analyses in two independent case-control sample sets. J Psychiatr Res. 2018; 96: 23-32.
  11. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol. 2003; 140(6): 1128-1136.
  12. Kowalska M, Nowaczyk J, Fijałkowski Ł,Nowaczyk A. Paroxetine— overview of the molecular mechanisms of action. Int J Mol Sci. 2021; 22(4): 1662.
  13. Park DI, Dournes C, Sillaber I, Ising M, Asara JM, Webhofer C, et al. Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin-proteasome systems. Transl Psychiatry. 2017; 7(4): e1078.
  14. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry. 1992; 53 Suppl: 21-26.
  15. Yankelevitch-Yahav R, Franko M, Huly A, Doron R. The forced swim test as a model of depressive-like behavior. J Vis Exp. 2015; (97): 52587.
  16. Guzzetti S, Calcagno E, Canetta A, Sacchetti G, Fracasso C, Caccia S, et al. Strain differences in paroxetine-induced reduction of immobility time in the forced swimming test in mice: role of serotonin. Eur J Pharmacol. 2008; 594(1-3): 117-124.
  17. Jin ZL, Chen XF, Ran YH, Li XR, Xiong J, Zheng YY, et al. Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function. Sci Rep. 2017; 7(1): 8631.
  18. Carboni L, Delafont B, Ivanchenko E, Ratti E, Learned SM, Alexander R, et al. Folate metabolism biomarkers from two randomized placebo-controlled clinical studies with paroxetine and venlafaxine. World J Biol Psychiatry. 2021; 22(4): 315-321.
  19. Young SN. Folate and depression--a neglected problem. J Psychiatry Neurosci. 2007; 32(2): 80-82.
  20. Khosravi M, Sotoudeh G, Amini M, Raisi F, Mansoori A, Hosseinzadeh M. The relationship between dietary patterns and depression mediated by serum levels of Folate and vitamin B12. BMC Psychiatry. 2020; 20(1): 63.
  21. Yurdakul D, Gürer ÜS, Rayaman E, Erçağ E, Haklar G, Çevikbaş A, et al. The effects of antidepressant drugs on polymorphonuclear leukocyte functions and levels of folic acid, vitamin B12, Zinc and Copper in Major Depression. Nobel Med. 2013; 9(1): 81-88.
  22. John S. The role of abnormalities related to the one carbon cycle in depression and schizophrenia. Neurosci Med. 2012; 1(3): 101-106.
  23. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol. 2005; 289(6): H2649-H2656.
  24. Kofler M, Schiefecker AJ, Gaasch M, Sperner-Unterweger B, Fuchs D, Beer R, et al. A reduced concentration of brain interstitial amino acids is associated with depression in subarachnoid hemorrhage patients. Sci Rep. 2019; 9(1): 2811.
  25. Woo HI, Chun MR, Yang JS, Lim SW, Kim MJ, Kim SW, et al. Plasma amino acid profiling in major depressive disorder treated with selective serotonin reuptake inhibitors. CNS Neurosci Ther. 2015; 21(5): 417-424.
  26. Pinto VL, de Souza PF, Brunini TM, Oliveira MB, Moss MB, Siqueira MA, et al. Low plasma levels of L-arginine, impaired intraplatelet nitric oxide and platelet hyperaggregability: implications for cardiovascular disease in depressive patients. J Affect Disord. 2012; 140(2): 187-192.
  27. Calabrese F, Guidotti G, Molteni R, Racagni G, Mancini M, Riva MA. Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment. PLoS One. 2012; 7(5): e37916.
  28. Yang P, Li X, Ni J, Tian J, Jing F, Qu C, et al. Alterations of amino Acid level in depressed rat brain. Korean J Physiol Pharmacol. 2014; 18(5): 371-376.
  29. Gołembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol. 2000; 52(6): 441-448.
  30. Ali-Sisto T, Tolmunen T, Viinamäki H, Mäntyselkä P, Valkonen-Korhonen M, Koivumaa-Honkanen H, et al. Global arginine bioavailability ratio is decreased in patients with major depressive disorder. J Affect Disord. 2018; 229: 145-151.
  31. Cao B, Deng R, Wang D, Li L, Ren Z, Xu L, et al. Association between arginine catabolism and major depressive disorder: A protocol for the systematic review and meta-analysis of metabolic pathway. Medicine (Baltimore). 2020; 99(27): e21068.
  32. Hess S, Baker G, Gyenes G, Tsuyuki R, Newman S, Le Melledo JM. Decreased serum L-arginine and L-citrulline levels in major depression. Psychopharmacology (Berl). 2017; 234(21): 3241-3247.
  33. Fukada S-i, Morita T,Sugiyama K. Effects of various amino acids on methionine-induced hyperhomocysteinemia in rats. Biosci Biotechnol Biochem 2008; 72(7): 1940-1943.
  34. MahmoudianDehkordi S, Ahmed A T, Bhattacharyya S, Han X, Baillie R A, Arnold M, et al. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Transl Psychiatry. 2021; 11(1): 1-14.
  35. Moaddel R, Shardell M, Khadeer M, Lovett J, Kadriu B, Ravichandran S, et al. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology. 2018; 235(10): 3017-3030.
  36. Finkel M S, Laghrissi-Thode F, Pollock B G,Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 1996; 32(4): 653-658.
  37. Baranyi A, Amouzadeh-Ghadikolai O, von Lewinski D, Rothenhäusler HB, Theokas S, Robier C, et al. Branched-Chain amino acids as new biomarkers of major depression - a novel neurobiology of mood disorder. PLoS One. 2016; 11(8): e0160542.
  38. Webhofer C, Gormanns P, Tolstikov V, Zieglgänsberger W, Sillaber I, Holsboer F, et al. Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. Transl Psychiatry. 2011; 1(12): e58.
  39. Hong SY, Yang DH, Chang SK. The relationship between plasma homocysteine and amino acid concentrations in patients with endstage renal disease. J Ren Nutr. 1998; 8(1): 34-39.
  40. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpé S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998; 97(4): 302-308.
  41. Park DI, Dournes C, Sillaber I, Uhr M, Asara JM, Gassen NC, et al. Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans. Sci Rep. 2016; 6: 35317.